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Renal function impairment goes along with a disturbed
calcium, phosphate, and vitamin D metabolism, resulting in
secondary hyperparathyroidism (sHPT). These mineral
metabolism disturbances are associated with soft tissue
calcifications, particularly arteries, cardiac valves, and
myocardium, ultimately associated with increased risk of
mortality in patients with chronic kidney disease (CKD). sHPT
may lead to cardiovascular calcifications by other
mechanisms including an impaired effect of parathyroid
hormone (PTH), and a decreased calcium-sensing receptor
(CaR) expression on cardiovascular structures. PTH may play
a direct role on vascular calcifications through activation of a
receptor, the type-1 PTH/PTHrP receptor, normally attributed
to PTH-related peptide (PTHrP). The CaR in vascular cells may
also play a role on vascular mineralization as suggested by its
extremely reduced expression in atherosclerotic calcified
human arteries. Calcimimetic compounds increasing the CaR
sensitivity to extracellular calcium efficiently reduce serum
PTH, calcium, and phosphate in dialysis patients with sHPT.
They upregulate the CaR in vascular cells and attenuate
vascular mineralization in uremic states. In this article,
the pathophysiological mechanisms associated with
cardiovascular calcifications in case of sHPT, the impact of
medical and surgical correction of sHPT, the biology of the
CaR in vascular structures and its function in CKD state, and
finally the role played by the CaR and its modulation by the
calcimimetics on uremic-related cardiovascular calcifications
are reviewed.
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More than a century after its identification, secondary
hyperparathyroidism (sHPT) is still observed in the majority
of patients with chronic kidney disease (CKD) stages 4–5, and
in more than one-third of patients treated by dialysis. Renal
function impairment goes along with a disturbed calcium,
phosphate, and vitamin D metabolism, resulting in sHPT.
These mineral metabolism disturbances are associated with
soft tissue calcifications, particularly arteries, cardiac valves,
and the myocardium, which are ultimately associated with
increased risk of morbidity and mortality.1 Compared with
age-matched subjects, CKD patients particularly present
more atherosclerotic plaques and a more rapid calcification
of these plaques and of the vascular media layer.2 Besides
mineral alterations, sHPT may also lead to cardiovascular
calcifications by other less known mechanisms, including
an impaired action of parathyroid hormone (PTH) and a
decreased expression of the calcium-sensing receptor (CaR)
on cardiovascular structures. The conventional therapy of
sHPT, generally used until the past 5–10 years, consisting of
calcium salts and supra-physiological doses of vitamin D
analogs, increases serum calcium and phosphate concentra-
tions and the risk of cardiovascular mineralization. Similarly,
radical treatment of sHPT, by subtotal or total surgical
parathyroidectomy (PTX), results in a permanent and
irreversible state of hypoparathyroidism, low bone remodel-
ing, and exposition to a high risk of hyperphosphatemia,
hypercalcemia, and cardiovascular calcifications.3 Thus,
innovative therapies of sHPT such as calcium-free intestinal
phosphate binders, lesser hypercalcemic vitamin D deriva-
tives, and calcimimetics might control parathyroid gland
hyperfunction, without significantly disturbing calcium
phosphate metabolism, while preventing cardiovascular
calcifications.
In this article, we review the pathophysiological mecha-
nisms associated with cardiovascular calcifications in case of
sHPT, the impact of medical and surgical correction of sHPT
on the progression of cardiovascular calcifications, the
biology of the CaR in vascular structures, and its function
in CKD state, and finally the role played by the CaR and its
modulation by the calcimimetics on uremic-related cardio-
vascular calcifications.
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EPIDEMIOLOGY AND CONSEQUENCES OF CARDIOVASCULAR
CALCIFICATIONS
Vascular and cardiac valve calcifications are more prevalent
and severe in CKD patients compared with healthy subjects of
the general population.4,5 Indeed, autopsy and clinical studies
have found an increased intima layer thickness and areas of
mineralization in coronary, renal, aorta, radial, and epigastric
arteries in 490% of CKD patients compared with only 30%
in age-matched control subjects. Similarly, media layer
thickness and calcifications are also more frequently found
in CKD patients than in control subjects, roughly 60% vs.
20%, respectively.2,6–9 Vascular calcifications also consistently
share the same five classical risk factors associated with the
presence and extent of these calcifications in the general
population, including advanced age, diabetes, hyperlipidemia,
inflammation, and tobacco use. In addition, dialysis treatment
itself exponentially accelerates the process of vascular miner-
alization.2,8,10–12
Once cardiovascular calcifications are installed, their
consequences can be overwhelming as suggested by their
association with an increased risk of fatal outcomes in CKD
patients, more than 50% of whom die from cardiovascular
complications including myocardial infarction, heart failure,
and sudden death.13 The consequences differ depending on
the type of calcification, arterial intima or media, and in the
heart, valvular or myocardial. Arterial intima calcification is
mostly secondary to calcification of atherosclerotic plaques,
which may increase the risk of arterial thrombosis, plaque
instability, and myocardial infarction. Arterial media calcifi-
cation leads to vessel stiffness, loss of vascular compliance,
increased wave pulse velocity, left ventricular hypertrophy,
diastolic dysfunction, coronary hypoperfusion, and finally
heart failure.14 It is also responsible for the rather exception-
ally observed calcifying uremic arteriopathy, which often leads
to necrotizing lesions of distal extremities and an extremely
high mortality rate. In the heart, myocardial calcification is
a rare cause of severe heart failure. Calcification of cardiac
valves is an important cause of both native and prosthetic and
mitral and aortic valve dysfunction. CKD patients with
cardiac valvular calcifications may also die, as do non-uremic
patients, from myocardial infarction, heat failure, and sudden
death.15
CALCIUM-SENSING RECEPTOR
The CaR is a 121-kDa protein with three main structural
domains characteristic of G-protein-coupled receptors. It has
a long extracellular N-terminal domain essential for the
interaction with its principal agonist ionized calcium, seven
hydrophobic membrane-spanning helices, which anchor it in
the plasma membrane, and an intracellular C terminus, which
has multiple regulatory protein kinase phosphorylation
sites.16 The CaR is a low-affinity receptor, as millimolar
concentrations of the agonists (3mmol/l for calcium) are
needed for its activation. It is also of limited selectivity as it
can be activated by numerous divalent or trivalent cations in
addition to calcium, and in order of potency, such as
La34Gd34Be24Ca24Ba24Sr24Mg2, and by other poly-
cationic compounds such as neomycin, spermine, and
numerous amino acids. It should be reminded that in clinical
practice many of these cations would never reach the
necessary plasma concentration to exert a calcimimetic effect
except Gd3 and Mg2. The activation of the CaR by any one of
the agonists leads to the stimulation of Gi protein,
phospholipase C, inositide triphosphate cascade, the mobili-
zation of intracellular calcium, and the activation of PKC. Its
activation also inhibits the adenylcyclase signaling pathway
and PKA.
The CaR is expressed in organs principally regulating
systemic calcium homeostasis, including kidney, intestine,
bone, thyroid, and the parathyroid glands. However, it is also
expressed in a variety of organs usually not thought to be
involved in calcium metabolism, such as brain, skin, breast,
testes, placenta, heart, and vessels. The consequence of the
activation of the CaR and the cascade of intracellular signal
pathways in parathyroid cells is the inhibition of PTH
secretion, whereas in the thyroid C cells it increases calcitonin
secretion, both effects leading to a reduction in serum calcium
concentration. Its activation in the other three organs may
also contribute to a further decrease in serum calcium; hence,
in the kidney it increases urinary calcium excretion, in bone it
decreases bone turnover, and in the intestine it decreases
intestinal absorption of calcium. The same CaR is also present
in the cardiovascular structures including aortic endothelial
and smooth muscle cells where it may exert multiple and not
yet fully elucidated physiological functions.17,18
COMPOUNDS MODULATING THE CALCIUM-SENSING
RECEPTOR
The molecular characterization of the CaR also led to the
discovery of several compounds capable of modulating its
function.19 The first ones have been called ‘type I calcimi-
metics’ because they mimic the effects of extracellular
calcium (eCa
2þ ). The second ones are called ‘type II
calcimimetics’ because they change the structural conforma-
tion of the CaR and stereoselectively increase its sensitivity to
eCa
2þ . Thus, when tested in in vitro studies, type II
calcimimetics appear to lose their effects in the absence of
eCa
2þ ; they do not really mimic the effect of eCa
2þ . The
third ones have been called ‘calcilytics’ because they inhibit
CaR function and stimulate PTH secretion. The mode of
action of calcimimetics and calcilytics resides on their
binding to distinct but overlapping regions of the extra-
cellular loops of the transmembrane domain. Besides
changing the structural conformation, calcimimetics can also
enhance CaR function by increasing its expression; inversely,
the calcilytics decrease parathyroid CaR expression. Several
calcimimetics have already been made. The first-generation
compounds, including NPS R-567, NPS S-567, NPS R-568,
and NPS S-568, were retired from clinical development
because of a low bioavailability (o1%). The second
generation includes AMG-073 and Calindol. These com-
pounds decrease the secretion of PTH in a dose-dependent
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manner, in cultured parathyroid cells and in healthy
animals. They also diminish serum calcium concentration
because of the decrease of PTH secretion, decreased
bone turnover, stimulation of calcitonin secretion, and
stimulation of the CaR in the kidney increasing calciuria.
The third generation of calcimimetics, and peptides with CaR
agonist properties, is already being developed, with two new
compounds, the AC-265347, which shows higher potency
than all previous calcimimetics,20 and the calcimimetic B,
which has a more specific action on the parathyroid
CaR and no stimulation of calcitonin secretion from thyroid
C cells.21
CALCIMIMETICS AND CARDIOVASCULAR CALCIFICATIONS
Direct effect of calcimimetics, in vitro and in vivo studies
A significant number of in vivo studies have suggested a direct
action of the CaR in vascular mineralization. First, it should
be reminded that the presence of a functional CaR in vascular
structures was a controversial issue until the demonstration of
its mRNA by real-time PCR, and its protein by immunostain-
ing, in aortic VSMC and in aortic endothelial cells.17,18 These
findings were confirmed and extended by the same methods
in normal renal artery from a human kidney donor and in the
epigastric artery from a recipient CKD patient.22–24 In
addition to VSMC, the CaR was also detected in endothelial
and perivascular cells.22–24 The receptor in VSMC is
functional as shown by the increase in intracellular calcium
and activation of the extracellular signal–regulated kinases
(ERK1/2) signaling pathway after treatment with calcium or
neomycin. Physiologically, the systemic activation of the CaR
by pharmacological doses of type II calcimimetics increases
vascular resistance in carotid, mesenteric, and hind limb
arteries, leading to a significant elevation of arterial blood
pressure in uremic and non-uremic animals.25 This effect is
probably mediated by a reduction in the activity of NO
synthase and hence local production of NO, also favored by
the decrease in ionized calcium, as suggested by the findings
that treatment with dose-dependently L-NAME blocked the
calcimimetic effect.25 These findings have been contested by
other observations showing that the calcimimetic cinacalcet
HCl induced a dose-dependent vasodilation of pre-contracted
aorta,17 and reduced arterial blood pressure in uremic rats
and in spontaneously hypertensive rats.26,27 It should never-
theless be stressed that no clinical evidence for a significant
effect of calcimimetics on blood pressure has been reported so
far.
The expression of the CaR is extremely reduced in
atherosclerotic calcified human arteries, which has suggested
that it could play a preventive role in vascular mineralization
when expressed normally.22 This observation has been
supported by the results of in vitro studies showing a marked
reduction of the CaR expression in bovine VSMC when they
are incubated in a mineralization medium containing a
calcium concentration between 1.8 and 2.5mmol/l, or with
gadolinium.22 Similarly, overexpression of a dominant-
negative CaR in the same cells augments mineral deposition.
Conversely, the incubation of these cells with the calcimi-
metic R-568 prevented calcium deposition, probably by
stimulating the expression and sensitivity of the CaR. This
effect may be comparable to the one observed in parathyroid
cells where calcimimetics upregulate the CaR expression.28
Additional in vitro studies have also demonstrated that
calcimimetics decrease calcification of human smooth muscle
cells when cultured in high-phosphate medium; this
inhibitory effect is abolished by the transfection in these
cells of a silencing CaR RNA (SiRNA-CaR),29 suggesting that
the direct activation of the CaR in vascular cells may slow
down the calcification process. Calcimimetics may also
prevent vascular calcifications by modulating the expression
of several genes involved in bone mineralization. Indeed, in
contrast to calcitriol, which downregulates the expression of
the transcription factor MGP (matrix gla protein), an
inhibitor of mineralization and upregulates the expression
of the calcification-promoting sodium-phosphate cotrans-
porter PiT-1, calcimimetics upregulate MGP and down-
regulate PiT1. Moreover, calcimimetics are able to decrease
the vascular expression of bone morphogenic protein-2 and
the osteoblastic transdifferentiation of VSMC.28 It should
also be pointed out that calcimimetics upregulated the
expression of CaR in vascular cells in uremic rats but not in
control rats.28 The activation of the CaR by calcimimetics
could also favor the regression of vascular calcifications
through the stimulation of macrophages or phagocytic cells
adjacent to calcified aortic lesions as found in an in vivo
model of 5/6th nephrectomized rats.30
Several animal models have also tried to demonstrate the
direct effect of calcimimetics on cardiovascular calcifications.
In the first one, the administration of cinacalcet HCl at the
oral dose of 10mg/kg/day for 26 consecutive days prevented
media aortic calcifications in 5/6th nephrectomized rats.
However, when coadministered with calcitriol (0.1 s.c. mg/
day), cinacalcet HCl controlled the calcitriol-induced hyper-
calcemia and hyperphosphatemia but did not attenuate
media vascular calcification.31 In the second one, calcimi-
metic NPS-R-568 alone reduced PTH and also prevented
some calcitriol-induced vascular calcification.32 The third
study showed that when uremic animals are fed with a high-
phosphate diet, accelerating the process of heart and vascular
calcification, the heart and aorta contained significantly
greater calcium deposition than control animals, and that the
increase in aorta calcium content was associated with an
increase in the expression of several osteogenic markers
including osteocalcin, osteopontin, and Runx-2 genes. Both
cinacalcet HCl and PTX prevented the calcifications in this
model, suggesting that the calcification process was led by
the excessively high PTH levels.33 A fourth study investigated
the effect of NPS-R-568 on cardiovascular calcification in the
ApoE/ mice, a hyperlipidic model of accelerated athero-
sclerosis rendered uremic by 5/6th nephrectomy.29 NPS-R-
568 efficiently reduced serum PTH, calcium, and phosphate
levels, and delayed the progression of both atherosclerotic
plaques and aortic calcification. The fifth observation, also in
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5/6th nephrectomized rats, showed that NPS-R-568 reduced
vascular remodeling, intima-media thickness, and arterial
calcification, whereas non-hypercalcemic doses of calcitriol
induced calcium deposition in the aorta of uremic and non-
uremic rats.28 Altogether, the results of these in vitro and
in vivo studies point toward a direct implication of the CaR
in the mechanisms of vascular function and mineralization.
Indirect effects of calcimimetics via PTH, calcium, and
phosphate
PTH. Conflicting results exist with regard to the role
played by continuously elevated PTH concentration on
cardiovascular calcifications (Figure 1). Physiologically, the
activation of the PTH/PTHrP receptor (PTHR1)34 by either
PTH or PTHrP decreases peripheral vascular resistances and
arterial blood pressure, which might protect against vascular
calcifications.35,36 Paradoxically, continuous high PTH is
associated with arterial hypertension rather than with
hypotension, which could be linked either to desensitization
or downregulation of its own receptor in vascular cells, or to
its renal effect on water and electrolyte balance. Indeed, PTH
directly stimulates the renin–angiotensin–aldosterone system,
as well as sympathetic activity and the secretion of cortisol,
which can lead to sodium and water retention and ultimately
to hypertension; these alterations may induce endothelial
dysfunction and promote vascular calcifications.37,38
Moreover, PTH such as PTHrP may decrease calcification
of cardiovascular cells, as PTHrP retards cartilage growth plate
mineralization by inhibiting transcription factors such as
Runx2/Cbfa1, Osterix, MSX2, and other pro-osteogenic
proteins and the dedifferentiation of VSMC into osteoblast-
like cells.39 PTHrP also prevents vascular calcification by
blocking the induction of alkaline phosphatase activity in
bovine VSMC through a PTHR1-dependent effect, which
differs from its nuclear effect.40–44 Indeed, PTHrP and PTHR1
are highly expressed in human and rat atherosclerostic lesions,
and, experimentally, endogenous whole PTHrP, conserving its
NLS residues (nuclear/nucleolar localization sequence),
stimulates VSMC proliferation, atheroma formation, and
ossification. However, when PTHrP lacks its NLS sequence,
after experimental removal, it cannot get to the nucleus and
instead inhibits proliferation and calcification, certainly
through the activation of the cell surface receptor PTHR1.
Thus, activation of the PTHR1 by PTH may have the same
inhibitory effect on vascular calcification as the NLS-deleted
PTHrP molecule. However, this protective effect may be
compromised in CKD patients because of an altered receptor
expression and function. In CKD, the PTHR1 is often
deregulated by several mechanisms including PTHR1 down-
regulation,45 accumulation of inhibitory PTH fragments
(PTH 7–84),46 and the excessive use of active vitamin D
derivatives, which leads to a reduced PTHR1 expression.47
The downregulation of the PTHR1 might also explain why the
administration of high doses of PTH in parathyroidectomized
uremic animal cannot prevent the induction of aorta
calcification even in the presence of normal circulating levels
of calcium and phosphate.48 It is noteworthy that situations
that are comparable to PTHR1 downregulation, such as in
case of low serum PTH levels and low bone turnover, as in
patients with iatrogenic or congenital hypoparathyroidism
states, appear to increase the risk of cardiovascular calcifica-
tions. This has also been observed in hemodialysis patients in
whom low serum PTH levels, resulting from extensive
PTX, are associated with high arterial calcification scores
(CAC).49,50 Nevertheless, in this situation of iatrogenic
hypoparathyroidism, it cannot be ruled out that the preceding
long-term exposure to excessive high PTH may have favored
cardiovascular calcifications. The correction of an adynamic
bone disease and calciphylaxis lesions by the administration of
human recombinant PTH in a dialysis patient also suggests a
protective effect of PTH on cardiovascular calcification.51
Therefore, it is tempting to speculate here that, in some
situations, the high circulating levels of PTH may try to
overcome the PTHR1 downregulation and protect against
vascular calcifications.
Calcium. Elevated calcium and phosphate concentrations
undoubtedly contribute to the pathophysiology of cardio-
vascular calcifications in CKD patients (Figure 2).52,53 Serum
Normal PTH High PTH
Vascular PTH/PTHrP receptor
(PTHR1) normally expressed
Prevents
cardiovascular calcifications
Promotes
cardiovascular calcifications
Vascular PTH/PTHrP receptor
(PTHR1) down-regulated
Normal arterial pressure
   Runx2/Cbfa1
   Osterix
   Msx2
   Alkaline phosphatase
   Arterial pressure
   Runx2/Cbfa1
   Osterix
   Msx2
   Alkaline phosphatase
Figure 1 | The role played by parathyroid hormone (PTH) on
cardiovascular calcifications in chronic kidney disease. PTHrP,
PTH-related peptide.
CaR
PTH
Calcium
Phosphate
Calcimimetics
CaR
MGP
Run2/Cbfa1
BMP2
Vascular CaRParathyroid CaR
Prevent cardiovascular
calcifications
Figure 2 |The role played by the vascular calcium-sensing
receptor (CaR) and calcimimetics on cardiovascular
calcifications in chronic kidney disease. MGP, matrix gla
protein; PTH, parathyroid hormone.
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calcium concentration decreases by 6–10% during the
treatment with calcimimetics, with the largest reduction
occurring during the first 6 weeks after treatment initiation,
and with the greatest reduction in patients with the highest
serum calcium and PTH levels.19 The mechanism responsible
for the calcium reduction under the calcimimetic therapy is
not fully understood, but it is highly probable that the decrease
in bone remodeling after lowering PTH by the calcimimetic
may reduce the exchange of calcium between extracellular
fluids and a miscible pool of calcium in bone. It is recognized
that high calcium concentration leads to the phenotypic
transformation of VSMC into osteoblast-like cells and
mineralization.7 Moreover, high-calcium medium stimulates
the expression of PiT1 in VSMC and increases the sensibility
to these cells to mineralize in the presence of high phosphate
levels.7,54 A high calcium concentration also promotes VSMC
calcification by stimulating the expression of alkaline phos-
phatase and by decreasing the expression of MGP.7,54 Thus, it
is plausible that by reducing serum calcium levels calcimi-
metics may protect against vascular mineralization.
Phosphate. Calcimimetics significantly reduced serum
phosphate levels certainly because of the decrease in bone
remodeling and by allowing the use of lower doses of active
vitamin D analogs, which potentially reduces intestinal
phosphate absorption. A high phosphate concentration
directly stimulates VSMC transformation in osteoblast-like
cells through the activation of PiT1 and the stimulation of
several transcription factors including Runx2/Cbfa1, osteo-
pontin, Msx2, and Osterix. The phosphate-induced VSMC
mineralization can be prevented by the inhibition of PiT1 and
the phosphate uptake, either by foscarnet or PiT siRNA.1,7
Phosphate can also induce vascular calcification by promoting
VSMC apoptosis and by facilitating the mineral nucleation of
apoptotic bodies.55 It is noteworthy that the reduction of
serum phosphate levels by the use of calcium-free intestinal
phosphate binders significantly attenuates the progression of
coronary artery CAC in dialysis patients as reported by several
recent randomized clinical trials including Treat-To-Goal,
RIND and DCOR.56,57 Therefore, by reducing serum phos-
phate levels, calcimimetics may attenuate the progression of
cardiovascular calcification.
Cinical data, the ADVANCE Study. The beneficial effect of
reducing serum PTH levels either by surgical PTX or by
medication in CKD patients with sHPT on vascular calcifica-
tions has not been definitely established. PTX may be
associated with both reduction and progression of cardiovas-
cular calcifications in these patients.58–61 Native and active
vitamin D analogs efficiently reduce serum PTH levels;
however, there is no scientific evidence demonstrating any
effect on the progression of cardiovascular calcifications. There
are several publications illustrating the healing of calciphylaxis,
painful cutaneous purpuric lesions that lead to tissue
calcification and ischemic necrosis, in CKD patients with
sHPT and treated with calcimimetics.62–64
The ADVANCE Study is the first and unique randomized
clinical trial that has assessed the effect of a calcimimetic
combined with low doses of active vitamin D (o6mg,
equivalent of paricalcitol/week), compared with flexible doses
of active vitamin D, on the progression of cardiovascular
calcifications in 320 adult hemodialysis patients with sHPT.65
All patients with hyperphosphatemia exclusively received
calcium-based phosphate-binding agents in order to reduce
potential confounding effects. Patients were stratified accord-
ing to their Agatston coronary artery calcification (CAC)
score: 30–399 (low to intermediate cardiovascular risk),
400–999 (moderate to high cardiovascular risk), and X1000
(extremely high cardiovascular risk). The primary end point
was the percentage change in Agatston CAC score from
baseline to week 52.65
What were the results obtained in this trial? Biochemical
parameters of bone and mineral metabolism, including
serum PTH, calcium, and phosphate, were better controlled
in the cinacalcet group than in the control group.66 At the
end of the study, 235 patients were available for efficacy
analysis, 115 patients in the cinacalcet group and 120 patients
in the control group. The median percentage increase in
Agatston CAC score from baseline to week 52 was 24% in the
cinacalcet group compared with 31% in the control group
(31–24¼ 7%, P¼ 0.073). Although this difference was not
statistically significant at the coronary arteries, the difference
between the two groups was statistically significant at the
aortic valve CAC (Po0.014), but not at the mitral valve. The
beneficial effect of the calcimimetic on the progression of
aortic valve calcification might be of clinical relevance
knowing the deadly association between aortic valve stenosis
and poor survival rate in dialysis patients.15,67,68 Interestingly,
when comparing the two groups with the volumetric score of
calcification, the increase in volume CAC score was 22% in
the cinacalcet group and 30% in the control group
(30–22¼ 8%, P¼ 0.009). The percentage of patients showing
an increase of415% in the Agatston CAC score was 37% in
the cinacalcet group versus 58% in the control group for
patients with a baseline score 41000.66 Moreover, a post-hoc
subgroup analysis showed that when the dose of vitamin D
was p6 mg/week (paricalcitol equivalent) in the group
receiving cinacalcet, the progression of cardiovascular
calcification was slower than that in the group receiving
flexible doses of vitamin D sterols; the increase in Agatston
CAC score was 17% in the cinacalcet group and 31% in the
control group (31–17¼ 14%, P¼ 0.017; ANZSN Abstract,
article submitted).
What is the importance of this trial to clinical practice?
The ADVANCE Study provides some useful information for
our daily clinical practice. The first one would be the
demonstration of the discrepancy between actual global
recommendations and what we have seen in this trial.
KDIGO does not give precise recommendation regarding the
evaluation or assessment of cardiovascular calcifications in
dialysis patients, methods, frequency, etc. Nevertheless, the
results of this study show that more than 50% of permanent
adult dialysis patients with serum PTH value 4300 pg/ml
actually have asymptomatic coronary calcification with a
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CAC score430. Owing to the association between coronary
calcifications and deleterious cardiac outcomes, we should
pay more attention to this issue and explore these patients
earlier. The second point is the clear demonstration of a
significant association between high serum PTH level and
CAC score. For each increase of 100 pg/ml in serum PTH,
there is a significant increase in the risk of CAC score after
adjusting for all the confounding variables. This suggests that
it would be worth keeping serum PTH values probably below
300 pg/ml in order to decrease the risk of cardiovascular
calcification and not over 500 pg/ml as recently recom-
mended by KDIGO. The third point is that we can medically
and efficiently control sHPT without surgery in the majority
of the patients and attenuate the progression of coronary,
aortic, and valvular calcifications in dialysis patients.
The ADVANCE Study had numerous limitations includ-
ing its short follow-up of only 52 weeks, a length of time
insufficient to detect substantial changes in vascular remo-
deling. In addition, the differences between groups were
probably less important because of the presence of active
vitamin D therapy in both groups, which resulted in a
moderate reduction of serum PTH levels in the control
group. The restriction placed on subjects’ use of calcium-
based phosphate binders helped to reduce the effects of co-
interventions; however, this restriction also limited the ability
to generalize the study’s results, as non-calcium-based
phosphate binders were commonly prescribed either alone
or in combination with calcium salts. Consequently, the
independent effect of cinacalcet on the progression of
vascular and cardiac valve calcification in patients treated
with sevelamer, lanthanum carbonate, and/or other non-
calcium-based phosphate binders remains to be determined.
Because the doses of vitamin D sterols differed substantially
between treatment groups, the slower progression of CAC
among subjects treated with cinacalcet plus low-dose vitamin
D sterols cannot be attributed solely to the use of cinacalcet.
CONCLUSION AND PERSPECTIVE
Cardiovascular calcifications in CKD patients display similar
risk factors as for the general population, with the exception
that they are more frequent, diffuse, severe, and rapidly
progressive particularly in dialysis patients. In addition, they
also added another major risk factor in CKD patients, sHPT
and its disturbed calcium phosphate metabolism. The control
of sHPT by calcimimetics and the simultaneous reduction of
serum calcium and phosphate, as well as the calcimimetic-
induced CaR upregulation in vascular cells, may attenuate the
progression of vascular calcification in CKD patients. The
results of the ADVANCE clinical trial generate the basis
for future interventional trials in this highly exposed
CKD population where the prevention and attenuation of
cardiovascular calcifications might certainly need more
than a single treatment focused on PTH and mineral
metabolism. The results from the ongoing EVOLVE Study
(Evaluation of Cinacalcet Therapy to Lower Cardiovascular
Events)69 will help determine whether the treatment by
calcimimetic can reduce the exceptionally high rates of mor-
tality and cardiovascular events among patients with sHPTon
hemodialysis.
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